Autologous CAR T-cell therapy engineered to target CS1 (SLAMF7/CD319) on multiple myeloma cells to induce T-cell–mediated cytotoxicity.
Autologous T cells are engineered to express a chimeric antigen receptor that binds CS1 (SLAMF7/CD319) on multiple myeloma cells, initiating antigen-dependent T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CS1-positive malignant plasma cells.
YES
DIRECT
CAR T cells recognize SLAMF7 on target cells, become activated, and kill via perforin/granzyme–mediated cytotoxicity (and related T cell effector pathways).
Subcutaneous CD3-directed T-cell engager bispecific antibody that binds CD3 on T cells and a B-cell tumor antigen to redirect cytotoxic T cells against malignant B cells.
Fully human effector-silent IgG1 trispecific antibody that binds CD79b and/or CD20 on B cells and CD3 on T cells, creating an immune synapse that activates and redirects cytotoxic T lymphocytes to lyse malignant B cells via TCR/CD3 signaling and perforin/granzyme-mediated killing.
YES
DIRECT
The trispecific T-cell–engaging antibody binds CD79b on B cells and CD3 on T cells, forming an immune synapse that activates CTLs to kill the CD79b+ cells via perforin/granzyme-mediated cytotoxicity.
Subcutaneous CD3-directed T-cell engager bispecific antibody that binds CD3 on T cells and a B-cell tumor antigen to redirect cytotoxic T cells against malignant B cells.
Fully human effector-silent IgG1 trispecific antibody that binds CD79b and/or CD20 on B cells and CD3 on T cells, creating an immune synapse that activates and redirects cytotoxic T lymphocytes to lyse malignant B cells via TCR/CD3 signaling and perforin/granzyme-mediated killing.
YES
DIRECT
Trispecific T‑cell engager binds CD20 on B cells and CD3 on T cells, forming an immune synapse that activates T cells to kill CD20+ cells via TCR/CD3 signaling and perforin/granzyme-mediated cytolysis.
Subcutaneous CD3-directed T-cell engager bispecific antibody that binds CD3 on T cells and a B-cell tumor antigen to redirect cytotoxic T cells against malignant B cells.
Fully human effector-silent IgG1 trispecific antibody that binds CD79b and/or CD20 on B cells and CD3 on T cells, creating an immune synapse that activates and redirects cytotoxic T lymphocytes to lyse malignant B cells via TCR/CD3 signaling and perforin/granzyme-mediated killing.
NO
INDIRECT
The antibody binds CD3 on T cells to activate and redirect them to kill CD79b/CD20-expressing B cells via perforin/granzyme; CD3+ T cells are not targeted for lysis.
Subcutaneous CD3-directed T-cell engager bispecific antibody that binds CD3 on T cells and a B-cell tumor antigen to redirect cytotoxic T cells against malignant B cells.
CD3-directed bispecific antibody (rezetamig) that binds CD3 on T cells and CD22 on B-lineage tumor cells, crosslinking them to form an immune synapse, activate TCR/CD3 signaling, and induce perforin/granzyme-mediated killing of CD22+ malignant B cells, with associated cytokine release.
NO
INDIRECT
The bispecific binds CD3 on T cells to activate them and bridge to CD22 on B cells; activated T cells kill CD22+ targets via perforin/granzyme, not CD3+ T cells.